Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
- Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
- Alegent Health Lakeside Hospital — Omaha, Nebraska
Phase 3 Recruiting Network
This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Nebraska: - NHO Revive Research Institute, LLC — Lincoln, Nebraska
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Nebraska: - University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095) — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Nebraska: - The Urology Center PC DBA UroHealth Partners — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Nebraska: - XCancer Omaha LLC — Omaha, Nebraska
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Sponsor: AstraZeneca
NCT ID: NCT07611110
Sites in Nebraska: - Research Site — Omaha, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Nebraska: - XCancer Omaha — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Nebraska: - University of Nebraska Medical Center Buffet Cancer Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Nebraska: - Urology Cancer Center, PC — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07590934
Sites in Nebraska: - Research Site — Omaha, Nebraska
Phase 2 Recruiting Industry
This is a four-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to ch…
Sponsor: Convergent Therapeutics
NCT ID: NCT06549465
Sites in Nebraska: - X Cancer Omaha / Urology Cancer Center — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT04868604
Sites in Nebraska: - XCancer — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Blue Earth Therapeutics Ltd
NCT ID: NCT05413850
Sites in Nebraska: - XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Nebraska: - Oncology Hematology West, PC dba Nebraska Cancer Specialists — Omaha, Nebraska
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in Nebraska: - XCancer Center Omaha/Urology Cancer Center — Omaha, Nebraska
Phase 1 Recruiting Industry
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07581184
Sites in Nebraska: - XCancer — Omaha, Nebraska
Phase 1 Recruiting Industry
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter i…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06531499
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Nebraska: - Mary Lanning Healthcare, Morrison Cancer Center — Hastings, Nebraska
- Faith Regional Health Services, Carson Cancer Center — Norfolk, Nebraska
- Great Plains Regional Medical Center — North Platte, Nebraska
- Methodist Estabrook Cancer Center — Omaha, Nebraska
- Nebraska Methodist Health System — Omaha, Nebraska
NA Recruiting Industry
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer di…
Sponsor: Pack Health
NCT ID: NCT05349227
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska